间充质干细胞（UC-MSCs）移植治疗SLE有一定效果，但其作用机制和治疗后的归巢和分布还不清楚。前期研究提示骨桥蛋白（OPN）参与了肾损伤过程并参与调控T细胞的分化形成。miRNA芯片技术发现：miRNA-181在SLE病人中表达下降，生物信息学预测其与调节T细胞分化的基因有关。为此，我们猜测：UC-MSCs移植后调节T细胞参与细胞介导的免疫反应影响 miRNA-181的表达，miRNA-181直接或间接调控OPN的表达，影响 Wnt、NF-KB等信号通路改善SLE病情。针对此假设，本研究拟多层次观察UC-MSCs移植治疗SLE的疗效，应用 WB、实时定量PCR和双荧光素酶报告基因载体分析mRNA181作用的靶基因及与骨桥蛋白的关系，探索其作用的信号通路，为临床治疗SLE和探讨SLE发病机制提供新思路。

Umbilical cord mesenchymal stem cells (UC-MSCs) transplantation in the treatment of SLE has certain effect, but the mechanism of homing and distribution after treatment is still not clear. Preliminary research suggests osteopontin (OPN) involving in the process of kidney injury and participating in the regulation of T cell differentiation. miRNA chip technology is found that the miRNA - 181 expressed in SLE patients, which predicts its bioinformatics and adjusts the genes of T cell differentiation. Therefore, we hypothesis: UC - MSCs transplantation could adjust T cells involving in cell-mediated immune response and affecting the expression of miRNA – 181.The miRNA - 181 directly or indirectly regulate the expression of OPN, affecting the Wnt, NF - KB signaling pathway to improve SLE patient. To this hypothesis, this research intends to observe from different aspects of effects of UC - MSCs transplantation in the treatment of SLE, applicating WB, real time quantitative PCR and dual luciferase reporter gene vector to analyze target genes mRNA181 role and relationship with osteopontin, and exploring the role of signaling pathways for clinical treatment of SLE ,and providing new ideas to explore the pathogenesis of SLE.